Business Description

Sanofi is involved in pharmaceutical product distribution, production, and research. The company was established in 1973. Its headquarters are in Paris, France. It has three business segments: Consumer Healthcare and Pharmaceuticals. The Pharmaceuticals segment includes the commercial operations of global franchises in specialty care, diabetes, cardiovascular, established prescription generics, and research, development, and production activities. The Consumer Healthcare segment includes commercial operations for their Consumer Healthcare products. The Vaccines section includes commercial operations for Sanofi Pasteur.

Key Financials

Revenue (US$ Mn)

• Sanofi’s annual revenue for 2021 was US$ 38,394 Mn, a -13.27% decrease from 2020
• The annual revenue generated by Sanofi in 2020 was US$ 44,267 Mn
• At a 2.63% increase, Sanofi’s annual revenue of US$ 40,456 Mn was indexed in 2019
• Sanofi generated total revenue of US$ 39,419 Mn in 2018

Operating Income (US$ Mn)

• Sanofi’s operating income for 2021 was US$ 8,262 Mn, a -52.43% decrease from 2020
• The operating income generated by Sanofi in 2020 was US$ 17,369 Mn
• At a -34.57% decrease from, Sanofi’s operating income of US$ 3,500 Mn was indexed in 2019
• Sanofi generated an operating income of US$ 5,348 Mn in 2018

Net Income (US$ Mn)

• Sanofi’s net income for 2021 was US$ 8,351 Mn, a -44.95% decrease from 2020
• The net income generated by Sanofi in 2020 was US$ 15,169 Mn
• At a -37.02% decrease from, Sanofi’s net income of US$ 3,177 Mn was indexed in 2019
• Sanofi generated a net income of US$ 5,044 Mn in 2018

Operating Margin %

• 22% was the operating margin generated by Sanofi in 2021
• Sanofi’s operating margin for 2020 was 39%, a 350.57% increase from 2019
• From 2018’s operating margins, Sanofi registered a -36.03% decrease in 2019, amounting to 9%
• An operating margin of 14% was generated in 2018 by Sanofi.

Gross Margin %

• Sanofi’s gross margin for 2021 was 70%, a -0.28% decrease from 2020
• The gross margin generated by Sanofi in 2020 was 70%
• At a 1.43% increase from , Sanofi’s gross margin of 71% was indexed in 2019
• Sanofi generated a gross margin of 70% in 2018

SWOT Analysis

Strengths

Strong R&D capabilities help Sanofi in keeping its product pipeline robust

Sanofi is a strong company in research and development (R&D). R&D at Sanofi covers a wide range of therapeutic areas, which are aligned with its Global Business Units. These include General Medicines & Emerging Markets and Sanofi Genzyme. Sanofi focuses on seven therapeutic areas (TAs), including diabetes, oncology, cardiovascular and metabolism, immunology and inflammation, multiple sclerosis and neurology, infectious diseases, and rare diseases.

These TAs are the driving force behind a number of R&D projects. These R&D facilities are part of the group’s scientific intelligence network. They facilitate knowledge-sharing and connections between scientists within the group and external partners. This allows for faster research. Sanofi invests heavily in R&D. This is a significant increase from the EUR5,894 spent in FY2019. The company had 91 projects under development as of December 2019 and 39 projects at the stage 3 stage. These projects are still waiting for approval. It manages four R&D centers in Asia, Europe, and North America.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data